Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Withdrawn before enrolling · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure

In brief

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral blood cells from treated and control subjects will be compared for mitochondrial respiratory function, oxidative damage, pro-inflammatory cytokines, and expression of antioxidant \& anti-electrophile genes.

Key facts

Study ID

NCT05408559

Run by

Texas Tech University Health Sciences Center

People needed

0

Starts

2022-07-01

Expected to finish

2026-01-01

Last updated by the study team

2026-06-29

Who can join

Age: 60 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age > 60 years
• Diagnosis of HFpEF (HF symptoms with a normal EF (>/=50 %)
• Ability to walk more than 500 feet (by self-report)
• Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study

You may not qualify if…

• Inability to provide informed consent
• Diagnosis of active cancer
• Inability to read and understand the SF-36 in English
• Participants using over the counter antioxidant supplements
• Participants with pulmonary or other issues which restrict walking capacity
• On oxygen therapy

Where it is running

• Texas Tech University Health Sciences Center (TTUHSC) — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.